CO6390102A2 - Combinacion anitumoral que comprende ave8062 y sorafenib - Google Patents

Combinacion anitumoral que comprende ave8062 y sorafenib

Info

Publication number
CO6390102A2
CO6390102A2 CO11149814A CO11149814A CO6390102A2 CO 6390102 A2 CO6390102 A2 CO 6390102A2 CO 11149814 A CO11149814 A CO 11149814A CO 11149814 A CO11149814 A CO 11149814A CO 6390102 A2 CO6390102 A2 CO 6390102A2
Authority
CO
Colombia
Prior art keywords
ave8062
sorafenib
anitumoral
combination including
formula
Prior art date
Application number
CO11149814A
Other languages
English (en)
Inventor
Brigitte Demers
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO6390102A2 publication Critical patent/CO6390102A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una combinación farmacéutica antitumoral que comprende AVE8062 de fórmula (I) y sorafenib de fórmula (II), pudiendo estar estos dos agentes antitumorales en forma de base o en forma de una sal de un ácido farmacéuticamente aceptable.
CO11149814A 2009-05-07 2011-11-04 Combinacion anitumoral que comprende ave8062 y sorafenib CO6390102A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0902210A FR2945210B1 (fr) 2009-05-07 2009-05-07 Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Publications (1)

Publication Number Publication Date
CO6390102A2 true CO6390102A2 (es) 2012-02-29

Family

ID=41402172

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11149814A CO6390102A2 (es) 2009-05-07 2011-11-04 Combinacion anitumoral que comprende ave8062 y sorafenib

Country Status (27)

Country Link
US (1) US20120108641A1 (es)
EP (1) EP2427185A1 (es)
JP (1) JP2012526090A (es)
KR (1) KR20120023754A (es)
CN (1) CN102438608A (es)
AR (1) AR076848A1 (es)
AU (1) AU2010244254A1 (es)
BR (1) BRPI1014197A2 (es)
CA (1) CA2761146A1 (es)
CL (1) CL2011002782A1 (es)
CO (1) CO6390102A2 (es)
CR (1) CR20110573A (es)
DO (1) DOP2011000335A (es)
EA (1) EA201171366A1 (es)
EC (1) ECSP11011440A (es)
FR (1) FR2945210B1 (es)
IL (1) IL216133A0 (es)
MA (1) MA33346B1 (es)
MX (1) MX2011011767A (es)
NI (1) NI201100191A (es)
PE (1) PE20120323A1 (es)
SG (1) SG175895A1 (es)
TN (1) TN2011000551A1 (es)
TW (1) TW201043225A (es)
UY (1) UY32618A (es)
WO (1) WO2010128259A1 (es)
ZA (1) ZA201108110B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2481404A1 (en) * 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
CN103140224A (zh) * 2010-06-18 2013-06-05 赛诺菲 包含奥瑞布林、紫杉烷衍生物和铂衍生物的抗肿瘤组合
FR2968557A1 (fr) * 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
ES2627120T3 (es) 2011-07-08 2017-07-26 Helmholtz-Zentrum für Infektionsforschung GmbH Medicamento para el tratamiento del cáncer de hígado
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
WO2015126903A1 (en) * 2014-02-18 2015-08-27 Health Research, Inc. Combination therapy for hepatocellular carcinoma
KR102272993B1 (ko) * 2019-07-09 2021-07-06 충남대학교산학협력단 퀴니딘 유도체를 유효성분으로 함유하는 항암보조제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
ATE328599T1 (de) * 1998-04-03 2006-06-15 Ajinomoto Kk Antitumorale mittel
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
ATE489080T1 (de) * 2001-06-25 2010-12-15 Ajinomoto Kk Antitumorale mittel
ATE529406T1 (de) * 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors

Also Published As

Publication number Publication date
NI201100191A (es) 2012-01-16
DOP2011000335A (es) 2011-12-15
TW201043225A (en) 2010-12-16
CA2761146A1 (fr) 2010-11-11
FR2945210A1 (fr) 2010-11-12
ECSP11011440A (es) 2011-12-30
CR20110573A (es) 2011-12-08
BRPI1014197A2 (pt) 2016-04-26
UY32618A (es) 2010-12-31
FR2945210B1 (fr) 2011-07-01
EA201171366A1 (ru) 2012-05-30
ZA201108110B (en) 2013-01-30
PE20120323A1 (es) 2012-04-17
AR076848A1 (es) 2011-07-13
IL216133A0 (en) 2012-01-31
MX2011011767A (es) 2012-02-28
EP2427185A1 (fr) 2012-03-14
JP2012526090A (ja) 2012-10-25
CL2011002782A1 (es) 2012-03-30
CN102438608A (zh) 2012-05-02
TN2011000551A1 (fr) 2013-05-24
KR20120023754A (ko) 2012-03-13
US20120108641A1 (en) 2012-05-03
MA33346B1 (fr) 2012-06-01
SG175895A1 (en) 2011-12-29
WO2010128259A1 (fr) 2010-11-11
AU2010244254A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
CO6390102A2 (es) Combinacion anitumoral que comprende ave8062 y sorafenib
AR077629A1 (es) Mimetico de smac
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
GT201200126A (es) Derivados de la cromenona con actividad anti-tumoral
ECSP11011327A (es) Derivados de aminotetralina, composiciones farmacéuticas que los contienen, y sus usos en terapia
CO6741228A2 (es) Inhibidores de la neprilisina
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
CY1115852T1 (el) Φαρμακευτικες συνθεσεις
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
EA201070237A1 (ru) Четвертичные опиоидные карбоксамиды
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
EA201071378A1 (ru) Дронедарон для предотвращения постоянной фибрилляции предсердий
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
IN2014DN10670A (es)
ECSP12011585A (es) Compuestos y composiciones para eltratamiento de enfermedades parasitarias
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
EA201490199A1 (ru) Терапевтические способы
CU20140028A7 (es) Compuesto de benzotiazolona
SV2010003773A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні

Legal Events

Date Code Title Description
FC Application refused